Drugmaker Insmed Inc said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million.
AstraZeneca will get $30 million in upfront fees and $120 million in various milestone payments, Insmed said.
20:41 Jose Bautista to re-sign with Blue Jays with one-year deal6
06:50 Pittsburgh Pirates avoid arbitration with Gerrit Cole, 4 others18
06:45 Cleveland Indians, closer Cody Allen avoid arbitration with $7.35M deal20
01:59 Houston Astros, LHP Dallas Keuchel avoid arbitration on $9.15M deal21